Zynerba Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 27
- Market Cap
- -
- Website
- http://www.zynerba.com
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05149898
- Locations
- 🇺🇸
Greenwood Genetic Center, Greenville, South Carolina, United States
🇦🇺Lady Cilento Children's Hospital - South Brisbane, Brisbane, Queensland, Australia
🇦🇺Genetics Clinics Australia, Melbourne, Victoria, Australia
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: PlaceboDrug: ZYN002 - transdermal gel
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT04977986
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Science 37, Culver City, California, United States
🇺🇸Amnova Clinical Research, LLC, Irvine, California, United States
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: ZYN002 - Cannabidiol Transdermal Gel
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT03802799
- Locations
- 🇺🇸
Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
🇺🇸Science 37, Culver City, California, United States
🇺🇸Amnova Clinical Research, LLC, Irvine, California, United States
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: ZYN002 - Cannabidiol Transdermal GelOther: Placebo Transdermal Gel
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Zynerba Pharmaceuticals, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT03614663
- Locations
- 🇺🇸
Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸UC Davis Health System, MIND Institute, Sacramento, California, United States